IFI-M · PBK Tri-Axis Balanced Series

Specimen SS-F-M3-01758 // MULTI-AXIS · IFI-M

PBK Tri-Axis Balanced Series II-PR

Brassica nigra

Black Mustard

Tier IIPBK Tri-Axis Balanced Series

Target Trait

1.38×

fold-change

Sharp+Bitter-Attenuation+Kokumi balanced tri-axis fold-change

Technical Specifications

SKU

SS-F-M3-01758

Genomic Edits

7

GC Content

45.3%

Construct Length

4,636 bp

Promoter System

Ubiquitin / T7

Expression System

Protoplast PEG-fusion

Host Strain

PEG-mediated

Receptor Target

TRPA1 + TAS2R38 (suppression) + CaSR

IFI Score

138

Pathway Edits

  • TRPA1 pathway primary gene cluster for sharp (IFI-P) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent PBK pathway operation
  • Cross-pathway regulatory circuit for balanced PBK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPA1, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredBalanced tri-axis expression strategy (PBK) with cross-pathway flux managementPEG-mediated co-transfection of axis constructs for rapid phenotypic screening of multi-axis combinations

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier II PBK triple-axis construct for advanced multi-modal sensory architecture combining sharp, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$699 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?